Glycovax Pharma Inc. has begun large-scale biomanufacturing of the CRM197 protein for use in numerous conjugate vaccines for human and animal vaccines.

The company will market this protein through its subsidiary, Espoir Therapeutics Inc., to meet the needs of vaccine development companies and research centers in the sector.

Glycovax has refined its production to meet regulatory requirements and standards for conjugate vaccine components for human and animal administration. The National Research Council of Canada (NRC) has developed a unique and highly efficient production system for CRM197.

To date, a handful of proteins have been used in conjugate vaccines, CRM197 being the most widely used due to its invaluable properties. Despite its important role, the large-scale production of CRM197 at a reasonable cost has been a limitation for vaccine developers. Glycovax Pharma aims to make the protein more affordable to protect the health of populations.

Dany Valiquette, President and CEO of Glycovax Pharma, said, “Over the next few months, we will be able to offer CRM197 to vaccine developers, whether pharmaceutical, biotech companies or university research institutions, guaranteeing them a large-scale, cost-effective, GMP-compliant manufacturing process. These developers will have the opportunity to evaluate our CRM197 with their own antigens, and Glycovax will support them in the regulatory aspects of their vaccine development.”